Schneider, V <br/><br/>
Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.  [electronic resource] 

 -  Leukemia  Aug 2014 
 - 1759-62 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2014.116  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ADP-ribosyl Cyclase 1--analysis<br/>Antigens, CD--analysis<br/>Antigens, CD34--analysis<br/>Humans<br/>Immunotherapy<br/>Interleukin-12--physiology<br/>Leukemia, Myeloid, Acute--genetics<br/>Mutation<br/>Neoplastic Stem Cells--metabolism<br/>Nuclear Proteins--genetics<br/>Nucleophosmin<br/>Receptors, Interleukin-12--genetics